title: Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism.
abstract: BACKGROUND
  We previously reported on four patients treated with PTH(1-84) who recovered from postoperative hypoparathyroidism many years after onset. Because vascular endothelial growth factor (VEGF) has been shown to be necessary for the induction of PTH-mediated angiogenesis, we postulated a possible role for VEGF in the recovery of parathyroid function in these subjects.
  
  
  OBJECTIVE
  Our objective was to measure VEGF levels in subjects with hypoparathyroidism who regained parathyroid gland function and matched controls.
  
  
  METHODS
  Subjects with hypoparathyroidism who regained parathyroid gland function were each matched to two hypoparathyroid controls by postoperative etiology, age (within 5 y), menopausal status, and duration of hypoparathyroidism. We measured serum VEGF levels at baseline and through 48 months of PTH(1-84) therapy.
  
  
  RESULTS
  VEGF levels increased after the initiation of PTH(1-84) therapy for the entire cohort, from 309.7 ± 162 pg/ml at baseline to 380.2 ± 178 pg/ml at 12 months (P = .03). Levels trended downward thereafter. There were no significant differences in VEGF levels between the subjects with recovery of parathyroid function and the matched controls.
  
  
  CONCLUSIONS
  PTH(1-84) alters serum VEGF levels in subjects with hypoparathyroidism. Additional investigation is necessary to understand the mechanisms by which some subjects with postoperative hypoparathyroidism recover parathyroid gland function.
authors.affiliation: Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.
authors.forename: Natalie E
authors.initials: NE
authors.lastname: Cusano
authors.forename: Mishaela R
authors.initials: MR
authors.lastname: Rubin
authors.forename: Chiyuan
authors.initials: C
authors.lastname: Zhang
authors.forename: Laura
authors.initials: L
authors.lastname: Anderson
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Levy
authors.forename: Aline G
authors.initials: AG
authors.lastname: Costa
authors.forename: Dinaz
authors.initials: D
authors.lastname: Irani
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007011:Hypoparathyroidism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007279:Injections, Subcutaneous; D008593:Menopause; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000502:physiology; D010280:Parathyroid Glands / Q000502:physiology*; D010281:Parathyroid Hormone / Q000008:administration & dosage*; D016105:Parathyroidectomy / Q000009:adverse effects; D011994:Recombinant Proteins / Q000008:administration & dosage; D013964:Thyroid Neoplasms / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D010281:Parathyroid Hormone; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A